clinical trial
Novo Nordisk shares positive results from COMBINE 3 phase 3a trial
January 10, 2024Research and Development Diabetes, IcoSema, Novo Nordisk, clinical trial, diabetes
Novo Nordisk has shared topline results from the COMBINE 3 phase 3a trial of once-weeklly IcoSema, a fixed-ration combination treatment …
Rhythm Pharmaceuticals and LG Chem Life Sciences enter license agreement
January 5, 2024Medical Communications LG Chem Life Sciences, License Agreement, Pharmacy, Rhythm Pharmaceuticals, clinical trial
Rhythm Pharmaceuticals and LG Chem Life Sciences have announced that they have entered into a global licensing agreement for LB54640, …
Tracon Pharmaceuticals shares update on ENVASARC phase 2 trial
December 21, 2023Research and Development ENVASARC, Pharmacy, Tracon Pharmaceuticals, clinical trial
Tracon Pharmaceuticals has shared an update from the ongoing phase 2 ENVASARC trial, which has now enrolled more than 70 …
InnoCare shares results from phase 2 trial for atopic dermatitis treatment
December 18, 2023Research and Development Dermatology, InnoCare, atopic dermatitis, clinical trial
InnoCare Pharma has announced phase 2 clinical trial results for its novel TYK2 (tyrosine kinase 2) inhibitor, ICP-332, which met …
First patient dosed in Cullinan Oncology’s phase 1 trial for CLN-617
December 15, 2023Research and Development Cullinan Oncology, Oncology, clinical trial, tumours
Cullinan Oncology has announced that the first patient has been dosed with CLN-617 in its phase 1 clinical trial, designed …
FDA approves Mission Therapeutics’ phase 2 clinical trial for acute kidney injury treatment
December 14, 2023Medical Communications FDA, Mission Therapeutics, Nephrology, acute kidney injury, clinical trial
Mission Therapeutics has announced that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application …
Merck and Moderna initiate phase 3 study of NSCLC treatment
December 13, 2023Medical Communications Merck, Moderna, NSCLC, Oncology, clinical trial
Merck (known as MSD outside of the US and Canada) and Moderna have announced the initiation of the phase 3 …
Regeneron shares data for multiple myeloma treatment
December 8, 2023Medical Communications Cancer, Oncology, Regeneron, clinical trial
Regeneron Pharmaceuticals has announced positive data from the pivotal LINKER-MM1 trial which assessed linvoseltamab as a treatment for patients with …
Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance
November 29, 2023Research and Development Oncology, Tolremo, clinical trial, drug resistance, solid tumours
Tolremo Therapeutics has announced that it has dosed the first patient in its first-in-human clinical trial to assess the safety, …
Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment
November 27, 2023Medical Communications COPD, Cardiology, Dupixent, Sanofi, clinical trial
Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for Dupixent as a treatment for …
GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment
November 27, 2023Medical Communications Blenrep, GSK, Oncology, clinical trial, multiple myeloma
GSK has announced positive results from a planned interim efficacy analysis of the phase 3 DREAMM-7 head-to-head trial which assessed …
Landos Biophama shares results from phase 1b trial for ulcerative colitis treatment
November 23, 2023Medical Communications Gastrointestinal tract, Landos Biopharma, clinical trial, ulcerative colitis
Landos Biopharma has announced that it has shared safety, tolerability, pharmacokinetics and clinical efficacy results for the NX-13 phase 1b …
MorphoSys shares phase 3 trial results for pelabresib in myelofibrosis treatment
November 23, 2023Research and Development Haematology, clinical trial, morphosys, myelofibrosis, pelabresib
MorphoSys has announced topline results from its phase 3 MANIFEST-2 study, which assessed pelabresib, an investigational BET inhibitor, in combination …
AstraZeneca’s Imfinzi meets primary endpoint for liver cancer treatment
November 13, 2023Research and Development AstraZeneca, Imfinzi, Oncology, clinical trial, liver cancer
AstraZeneca has announced positive results from the EMERALD-1 phase 3 trial for Imfinzi (durvalumab) in combination with transarterial chemoembolisation (TACE) …
First patient dosed in AdvanCell’s phase 1/2 trial for prostate cancer treatment
November 9, 2023Research and Development AdvanCell, Cancer, Oncology, clinical trial, prostate cancer
AdvanCell has announced that the first patient has been dosed with 212Pb-ADVC001 in its phase 1/2 trial for the PSMA-positive …
Latest content
FibroFind appoints Lee Borthwick as CEO
